Tharimmune (NASDAQ:THAR) Shares Down 0.5% – Time to Sell?

Shares of Tharimmune, Inc. (NASDAQ:THAR) dropped 0.5% during mid-day trading on Tuesday . The stock traded as low as $3.92 and last traded at $4.05. Approximately 588,151 shares were traded during trading, a decline of 60% from the average daily volume of 1,476,877 shares. The stock had previously closed at $4.07.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tharimmune in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Tharimmune currently has an average rating of “Sell”.

Tharimmune Trading Down 0.5%

The company has a market capitalization of $152.81 million, a price-to-earnings ratio of -1.02 and a beta of 1.43. The firm has a 50-day simple moving average of $4.15 and a two-hundred day simple moving average of $3.39.

Institutional Investors Weigh In On Tharimmune

Institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC bought a new stake in Tharimmune in the fourth quarter valued at $9,854,000. Clear Street Group Inc. acquired a new position in Tharimmune during the 4th quarter worth $5,066,000. Feynman Point Asset Management LLC acquired a new position in shares of Tharimmune during the fourth quarter valued at $1,314,000. Marshall Wace LLP bought a new position in Tharimmune in the fourth quarter valued at about $1,030,000. Finally, Geode Capital Management LLC increased its position in Tharimmune by 1,102.6% in the fourth quarter. Geode Capital Management LLC now owns 335,923 shares of the company’s stock worth $1,018,000 after purchasing an additional 307,991 shares during the period. 1.16% of the stock is owned by institutional investors and hedge funds.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.